Sandy Blackadder Primrose

Arquer Diagnostics Ltd. develops proprietary diagnostic immunoassays for the detection of prostate and bladder cancer using urine samples. Its develops non-invasive, urine-based ELISA and Point-of Care tests meet the increased demand for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes. The firm will commercialise ELISA and point-of-care urine tests for prostate and bladder cancer for use in the urology clinic, hospital lab and the GP’s surgery. The company was founded by David Nicholas Miller-Jones and William Dawson in 2007 and is headquartered in Sunderland, the United Kingdom.

The Pirbright Institute, founded in 1914, is based in Woking, UK. The institute specializes in preventing and controlling viral diseases of livestock and those that spread from animals to people. The British company's facilities and capabilities provide opportunities for collaboration with other institutes and industries in research, data analysis, training, and access to some areas on-site. The institute offers a range of products, including positive sera, inactivated antigens, diagnostic kits, viral cultures, and live midges. The non-profit company's high containment facilities are internationally groundbreaking in design and maintenance, and they provide consultancy in architecture, engineering, and highly specialized expertise in risk and assurance. The diagnostic development team works with the world reference laboratory for foot-and-mouth disease at the Pirbright Institute and external partners to provide diagnostic products for foot-and-mouth disease (FMD), swine vesicular disease (SVD), and peste des petit ruminants (PPR).

Glycoscoredx Ltd. develops a novel blood test that revolutionizes how prostate cancer is diagnosed. The company is based in Newcastle upon Tyne, UK. The British company was founded in 2020 by Jennifer Munkley. Allan Brown has been the CEO of the company since 2020.

Arrayjet Ltd. develops and produces microarray printing technologies for researchers, drug development groups, and diagnostic companies. Its products include Sprint, Marathon and Super Marathon, Ultra Marathon I and II Microarrayers. The company was founded by Howard John Manning, Peter Ghazal and Douglas Roy in 2000 and is headquartered in Roslin, the United Kingdom.

At Lab901 the management believe that your time should be dedicated to discovery, not manual and repetitive tasks. Lab901 was founded in 2001 to deliver this vision. Its team combines expertise in automation, electrophoresis, software development and molecular biology biochemistry. The company is proud to introduce ScreenTape, the first fully automated platform for gel electrophoresis.

Fios Genomics Ltd. provides genomic and bioinformatics data analysis services. It offers access to a combined resource of in-house bioinformaticians, statisticians and biologists working together to analyze, interpret genomic, transcriptomic and proteomic data. The company was founded by Peter Ghazal in 2008 and is headquartered in Edinburgh, the United Kingdom.